OLFML2B

Across TCGA pan-cancer cohorts, OLFML2B mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated OLFML2B data layer compared with 27 for mass-spec protein and 12 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher OLFML2B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated OLFML2B expression acts as an unfavorable survival marker, although some lineages such as OV and CCRCC show a favorable association.

GBM, OV, and CCRCC are the cancer types where OLFML2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.617	0.825	<.001	20	view →
OV	DFS	Tertile	All	1.000	0.801	.036	8	view →
CCRCC	DFS	Tertile	II,III,IV	0.780	0.232	.011	8	view →
PDAC	OS	Quartile	II,III,IV	0.571	0.993	.017	7	view →
LUAD	OS	Median	III,IV	0.231	0.627	.048	2	view →
LSCC	DFS	Median	III,IV	0.908	0.684	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

OLFML2B–GBM (DFS)

Open the GBM breakdown →